title: Effect of the haloperidol tetrahydropyridine metabolite 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6- tetrahydropyridine on dopamine receptor and transporter binding. A nonhuman primate 123I-iodobenzamide and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane single photon emission computed tomographic study.
abstract: Researching the biological activities and toxicities of metabolites of drugs is of growing importance and has received increasing attention during the last decade in order to gain a better understanding of the efficacy and safety profile of drugs in clinical use. HPTP (4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3, 6-tetrahydropyridine, CAS 52669-92-8), the tetrahydropyridine metabolite of the classical neuroleptic, haloperidol (CAS 52-86-8), has recently been the focus for further understanding the well-known side effect profile of haloperidol. The current study was aimed at investigating the effect of HPTP treatment on dopamine receptor and transporter binding in the nonhuman primate, i.e. the baboon Papio ursinus. The study was performed using the dopamine receptor ligand, 123-I-iodobenzamide (IBZM) and the dopamine transporter ligand, [123]2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane (beta-CIT) in planar scintigraphy and single photon emission computed tomographic (SPECT) protocols. Dopamine receptor binding in the striatum was measured from the time activity curves by calculating the IBZM ratios of the basal ganglia to frontal cortex and of the basal ganglia to cerebellum. 99mTc-HMPAO (hexamethylpropylene amine oxime) SPECT detected no changes in striatal perfusion during HPTP treatment. The transporter binding was measured by dynamic imaging of the basal ganglia, frontal cortex and cerebellum using beta-CIT. IBZM dopamine receptor binding is initially (as measured after 18 weeks treatment) decreased by HPTP treatment in the basal ganglia, frontal cortex (not significantly) and cerebellum but reversed to control values in the frontal cortex, as measured after 58 weeks treatment with HPTP. The binding to the basal ganglia and to a lesser degree the cerebellum is still affected after 58 weeks treatment with HPTP but indicates a tendency to return towards the control values. The results of the planar dynamic study with beta-CIT indicate a decrease in the beta-CIT binding to the dopamine transporters in the basal ganglia and to a lesser extent the cerebellum as measured by the time activity and percentage washout rate of the beta-CIT in the HPTP treated baboons. The effect of HPTP on the serotonin transporters appears to be minimal as observed from the results obtained from the frontal cortex. These results indicate that HPTP treatment influences both presynaptic and postsynaptic neurofunction in the dopaminergic neurones.
authors.affiliation: Department of Pharmacology, Potchefstroom University for Christian Higher Education, Potchefstroom, South Africa.
authors.forename: D W
authors.initials: DW
authors.lastname: Oliver
authors.forename: I C
authors.initials: IC
authors.lastname: Dormehl
authors.forename: C J
authors.initials: CJ
authors.lastname: Van der Schyf
authors.forename: J L
authors.initials: JL
authors.lastname: Neumeyer
authors.forename: N
authors.initials: N
authors.lastname: Hugo
authors.forename: R
authors.initials: R
authors.lastname: Keeve
authors.forename: N T
authors.initials: NT
authors.lastname: Rossouw
authors.forename: H W
authors.initials: HW
authors.lastname: Müller-Gärtner
authors.forename: N
authors.initials: N
authors.lastname: Castagnoli
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001549:Benzamides; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D002352:Carrier Proteins / Q000187:drug effects*; D003042:Cocaine / Q000031:analogs & derivatives; D004298:Dopamine / Q000378:metabolism*; D050483:Dopamine Plasma Membrane Transport Proteins; D006220:Haloperidol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D007457:Iodine Radioisotopes; D008297:Male; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D010215:Papio; D011759:Pyrrolidines; D011954:Receptors, Dopamine / Q000187:drug effects*; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D014150:Antipsychotic Agents; D001549:Benzamides; D002352:Carrier Proteins; D050483:Dopamine Plasma Membrane Transport Proteins; D007457:Iodine Radioisotopes; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D011759:Pyrrolidines; D011954:Receptors, Dopamine; C069723:2beta-carbomethoxy-3beta-(4-iodophenyl)tropane; C101091:4(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydropyridine; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; D003042:Cocaine; D006220:Haloperidol; D004298:Dopamine